RA Capital Management’s Janux Therapeutics JANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $258M | Hold |
11,189,693
| – | – | 4.35% | 4 |
|
|
2025
Q1 | $302M | Buy |
11,189,693
+824,041
| +8% | +$22.2M | 5.05% | 4 |
|
|
2024
Q4 | $555M | Buy |
10,365,652
+1,200,000
| +13% | +$64.2M | 7.39% | 3 |
|
|
2024
Q3 | $416M | Hold |
9,165,652
| – | – | 4.8% | 3 |
|
|
2024
Q2 | $384M | Hold |
9,165,652
| – | – | 5.08% | 3 |
|
|
2024
Q1 | $345M | Hold |
9,165,652
| – | – | 4.39% | 4 |
|
|
2023
Q4 | $98.3M | Hold |
9,165,652
| – | – | 1.54% | 16 |
|
|
2023
Q3 | $92.4M | Buy |
9,165,652
+495,008
| +6% | +$4.99M | 1.82% | 15 |
|
|
2023
Q2 | $103M | Hold |
8,670,644
| – | – | 1.94% | 13 |
|
|
2023
Q1 | $105M | Hold |
8,670,644
| – | – | 2.38% | 12 |
|
|
2022
Q4 | $114M | Hold |
8,670,644
| – | – | 2.32% | 14 |
|
|
2022
Q3 | $117M | Hold |
8,670,644
| – | – | 2.5% | 10 |
|
|
2022
Q2 | $106M | Hold |
8,670,644
| – | – | 2.82% | 7 |
|
|
2022
Q1 | $124M | Hold |
8,670,644
| – | – | 2.71% | 7 |
|
|
2021
Q4 | $171M | Hold |
8,670,644
| – | – | 3.02% | 5 |
|
|
2021
Q3 | $188M | Hold |
8,670,644
| – | – | 2.6% | 8 |
|
|
2021
Q2 | $216M | Buy |
+8,670,644
| New | +$216M | 3.47% | 4 |
|